- Home
- products
- south korea
- genomics redefines the boundaries of fungal genomics
Show results for
Refine by
Genomics Redefines The Boundaries Of Fungal Genomics Equipment Supplied In South Korea
11 equipment items found
Manufactured by:Celemics, Inc. based inSeoul, SOUTH KOREA
Celemics’ G-Mendeliome Clinical Exome Sequencing (CES) Panel is designed to overcome the limitations of analyzing clinical diseases with conventional whole-exome ...
Manufactured by:GeneAll Biotechnology Co., Ltd. based inSongpa-gu, SOUTH KOREA
GeneAll® Hybrid-R Blood RNA is a complete kit with ready-to-use reagent for the isolation of total RNA from up to 0.25 ml whole blood sample. This kit utilizes the lysis method of RiboEx™ LS which has a powerful ability of cell-lysis and the purification method based on glassfiber membrane technology. Fast and convenient procedure of Hybrid-R™ Blood RNA takes only 30 minutes for ...
Manufactured by:Celemics, Inc. based inSeoul, SOUTH KOREA
Celemics’ Oncorisk Panel is specifically designed to analyze hereditary cancer associated genes. The OncoRisk Panel targets 31 well-known oncogenes, leading to a reduction of totalsequencing cost compared to whole genome sequencing or whole exome sequencing. Additionally, if the gene of interest does not exist on the panel, it can be added separatelythrough our gene add-on service. This ...
Manufactured by:TxinnoBioscience Inc. based inYongin-si, SOUTH KOREA
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), is a type II transmembrane protein with nucleotide pyrophosphatase and phosphodiesterase enzymatic activities. Recently, ENPP1 has been found to play an important role in regulating STING pathway. By hydrolyzing cGAMP (natural ligand of STING) into AMP and GMP, ENPP1 negatively regulates STING-mediated type I interferon production and ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
WX presents biomarkers, based on raw transcriptome data. It is an artificial intelligence technology that can predict biomarkers, prognostic biomarkers and even the mode of action (MOA) of disease ...
Manufactured by:Bruker Corporation based inBillerica, MASSACHUSETTS (USA)
Optofluidic Technology is the Key to Faster Workflows and Deeper Data. See how opto-electropositioning (OEP) technology moves Cell Biology to light speed. Our technology combines precise cell processing, time-saving workflow automation, and rich, deep profiling. Watch this video animation, to see how Berkeley Lights advanced technology works. Welcome to the ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology. It specializes in genome data analysis, biomarker prediction, molecule selection and optimization. DEARGEN discovers new disease targets with Dr.UG and further realizes precision medicine by designing small molecules for new ...
Manufactured by:Celemics, Inc. based inSeoul, SOUTH KOREA
“Unlike Whole Genome Sequencing, Targeted Sequencing is a technique that selectively analyzes specific regional sequences of genomes.” Our Target Enrichment Panel uses hybridization-based capture technology to enable the core process of Target Sequencing, which is the separation and analysis of specific regional sequences of entire genomes. It can also accurately analyze all types of ...
Manufactured by:TPC Mechatronics based inSeo-gu, SOUTH KOREA
ISO 13485(Medical device quality control) certification. Standard Deep Well Plate(Open Platform) application. Reasonable Price(70% compared to competitors), High performance. ...
Manufactured by:LISCure Biosciences Inc. based inSeongnam-si, SOUTH KOREA
The LMT (LISCure Microbiology-based Technology) platform is an innovative tool to keep discovering and analyzing microbial and genome-based drug candidates. LMT (LISCure Microbiology-based Technology) Platform Consists of the Therapeutic Screening Platform, Microbial Optimization Platform, and Microbiome Database ...
Manufactured by:IMB Dx, Inc. based inSeoul, SOUTH KOREA
Tissue specimens are either from surgical resections or biopsies which may raise the risk of bleeding, and infection and further require recovery from the procedure. Genomic profiling of tissue samples provides a single point in space and time which is lacking the ability to reveal tumor heterogeneity and to test repeatedly to monitor the treatment efficacy. The risk of tissue biopsy is much ...